Mezzasalma Advisors LLC Purchases Shares of 50,654 Exelixis, Inc. (NASDAQ:EXEL)

Mezzasalma Advisors LLC acquired a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 50,654 shares of the biotechnology company's stock, valued at approximately $1,870,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Coppell Advisory Solutions LLC acquired a new position in Exelixis in the fourth quarter valued at approximately $25,000. Colonial Trust Co SC boosted its stake in Exelixis by 616.9% in the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 765 shares during the period. Principal Securities Inc. boosted its stake in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in Exelixis in the fourth quarter valued at approximately $39,000. Finally, Crowley Wealth Management Inc. acquired a new position in Exelixis in the fourth quarter valued at approximately $50,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EXEL has been the subject of a number of research reports. Stifel Nicolaus lifted their target price on Exelixis from $36.00 to $38.00 and gave the company a "hold" rating in a research note on Wednesday, May 14th. Wall Street Zen downgraded Exelixis from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 15th. Citigroup boosted their price objective on Exelixis from $45.00 to $56.00 and gave the stock a "buy" rating in a research report on Thursday, May 15th. UBS Group reiterated an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $47.00 price objective (up from $40.00) on shares of Exelixis in a research report on Thursday, June 12th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Exelixis has a consensus rating of "Moderate Buy" and an average target price of $39.76.

Insiders Place Their Bets

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of the company's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $43.09, for a total value of $324,683.15. Following the transaction, the director now owns 358,882 shares of the company's stock, valued at approximately $15,464,225.38. This represents a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Dana Aftab sold 1,508 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total value of $58,812.00. Following the completion of the transaction, the executive vice president now directly owns 693,181 shares in the company, valued at $27,034,059. This represents a 0.22% decrease in their position. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock worth $21,024,817 over the last ninety days. Company insiders own 2.82% of the company's stock.

Exelixis Stock Down 1.5%

EXEL traded down $0.61 during trading on Thursday, reaching $40.74. The stock had a trading volume of 2,701,447 shares, compared to its average volume of 2,369,176. The firm has a market capitalization of $11.11 billion, a price-to-earnings ratio of 18.52, a price-to-earnings-growth ratio of 0.83 and a beta of 0.28. Exelixis, Inc. has a 1-year low of $21.36 and a 1-year high of $48.85. The stock has a 50 day moving average of $40.20 and a two-hundred day moving average of $37.01.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.